Neuros Medical announced the closing of an oversubscribed $56 million Series D financing round. The funding will support US commercialization and further development of its Altius Direct Electrical Nerve Stimulation System, a non-opioid treatment for chronic post-amputation pain that has been approved by the US Food and Drug Administration.
The round was led by new investor EQT Life Sciences, with participation from existing investors including US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, Aperture Venture Partners.
Neuros Medical announced the closing of an oversubscribed $56 million Series D financing round. The funding will support US commercialization and further development of its Altius Direct Electrical Nerve Stimulation System, a non-opioid treatment for chronic post-amputation pain that has been approved by the US Food and Drug Administration.
The round was led by new investor EQT Life Sciences, with participation from existing investors including US Venture Partners, Amzak Health, Osage University Partners, Sectoral Asset Management, and Aperture Venture Partners.
